Image

Malaysia Blood Plasma Market – Industry Trends and Forecast to 2030

Pharmaceutical

Image

Malaysia Blood Plasma Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Sep 2023
  • Country Level
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Malaysia Blood Plasma Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 3,372.00 USD million
Diagram Market Size (Forecast Year) USD 6,521.00 USD million
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Malaysia Blood Plasma Market, By Type (Hyperimmune Globulin, Albumin, Factor VIII, Factor IX, Immunoglobulin,  Others), Mode of Delivery (Infusion Solutions, Gels, Sprays, Biomedical Sealants), Therapeutic Indication (Immunology, Oncology, Pulmonology, Rheumatology, Transplantation, Neurology, Hematology, Other), Application (Hypogammaglobulinemia, Immunodeficiency Diseases, Hemophilia, Von Willebrand's Disease (vWD), Others), End-User (Clinics, Hospitals, Other) - Industry Trends and Forecast to 2030.

Malaysia Blood Plasma Market Analysis and Size:

The increasing demand for plasma-derived medicines acts as one of the major factors driving the growth of blood plasma market. The advancements in medical technology and increasing health care infrastructure expenditure accelerate the blood plasma market growth.

Data Bridge Market Research analyses that the Malaysia blood plasma market which was USD 3,372 million in 2022, is expected to reach USD 6,521 million by 2030, and is expected to undergo a CAGR of 4.20 % during the forecast period. This indicates that the hyperimmune globulin segment dominates the type segment of the blood plasma market owing to the advancements in technology have led to the development of advancements in blood plasma products for various use. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Malaysia Blood Plasma Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

By Type (Hyperimmune Globulin, Albumin, Factor VIII, Factor IX, Immunoglobulin,  Others), Mode of Delivery (Infusion Solutions, Gels, Sprays, Biomedical Sealants), Therapeutic Indication (Immunology, Oncology, Pulmonology, Rheumatology, Transplantation, Neurology, Hematology, Other), Application (Hypogammaglobulinemia, Immunodeficiency Diseases, Hemophilia, Von Willebrand's Disease (vWD), Others), End-User (Clinics, Hospitals, Other)

Countries Covered

U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa

Market Players Covered

CSL Limited (Australia), Grifols, S.A.(Spain), Takeda Pharmaceutical Company Limited (Japan) and Octapharma AG (Switzerland)

Market Opportunities

  • Increased awareness and screening for blood-related diseases:
  • Government support and regulations

Market Definition

It refers to the market for the collection, processing, and distribution of blood plasma in Malaysia. Blood plasma is the yellowish liquid component of blood that remains after red blood cells, white blood cells, platelets, and other cellular components have been removed. It plays a crucial role in maintaining overall health and contains various proteins, antibodies, clotting factors, and nutrients.

Malaysia Blood Plasma Market Dynamics

Drivers

  • Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases such as cancer, autoimmune disorders, and hemophilia drives the demand for blood plasma-based therapies. Plasma-derived products such as immunoglobulins, clotting factors, and albumin are essential for the treatment of these conditions

  • Growing Aging Population

Malaysia, such as many other countries, has a growing aging population. Elderly individuals are more susceptible to various health conditions, including immune disorders and coagulation disorders. The need for blood plasma-based therapies increases with the aging population, thereby driving the market growth

  • Technological Advancements

Advances in technology have significantly improved the collection, processing, and storage of blood plasma. Automation, better testing methods, and increased efficiency in plasma fractionation processes have made plasma-derived products more accessible and reliable, driving market growth

Opportunities

  • Increased Awareness and Screening for Blood-Related Diseases

Awareness campaigns, public health initiatives, and increased screening for blood-borne diseases have led to the identification of more individuals who require plasma-based therapies. This has created a larger patient pool and subsequently increased the demand for blood plasma products

  • Government Support and Regulations

The Malaysian government plays a crucial role in regulating and promoting the blood plasma market. Favorable policies, regulations, and support for the development and distribution of plasma-derived products encourage market growth and investment in the sector

Restraints/Challenges

  • Regulatory Challenges

The blood plasma market is subject to stringent regulations and guidelines to ensure the safety and quality of the collected plasma. Compliance with these regulations can pose challenges for market participants, including obtaining necessary approvals, meeting quality standards, and adhering to safety protocols

  • Limited Donor Pool

The availability of suitable blood plasma donors can be a restraint. The eligibility criteria for plasma donation can be quite restrictive, including factors such as age, health conditions, and previous medical history. This limited pool of eligible donors may impact the overall supply of blood plasma in the market

This Malaysia blood plasma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Recent Developments

  • In May 2023, Teva Pharmaceutical Industries Ltd. announced a new strategic framework with four main pillars to position the Company for a new era of growth. This strategy aims to bolster the Company’s strong commercial portfolio with AUSTEDO®, AJOVY®,UZEDYTM and biosimilars, amplify its innovative pipeline, sustain its generics powerhouse and focus the business
  • In November 2022, A wholly-owned subsidiary of Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) and Sun Pharma Advanced Research Company Ltd

Malaysia Blood Plasma Market scope

The Malaysia blood plasma market is segmented on the basis of type, mode of delivery, therapeutic indication, application, and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Hyperimmune Globulin
  • Albumin
  • Factor VIII
  • Factor IX
  • Immunoglobulin
  • Others

Mode of Delivery

  • Infusion Solutions
  • Gels
  • Sprays
  • Biomedical Sealants

Therapeutic Indication

  • Immunology
  • Oncology
  • Pulmonology
  • Rheumatology
  • Transplantation
  • Neurology
  • Hematology
  • Other

Application

  • Hypogammaglobulinemia
  • Immunodeficiency Diseases
  • Hemophilia
  • Von Willebrand's Disease (vWD)
  • Others

End-User

  • Clinics
  • Hospitals
  • Other

Competitive Landscape and Malaysia Blood Plasma Market Share Analysis

The Malaysia blood plasma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Malaysia blood plasma market.

Some of the major players operating in the Malaysia blood plasma market are

  • CSL Limited (Australia)
  • Grifols, S.A.(Spain)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Octapharma AG (Switzerland)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

Malaysia Blood Plasma Market will be worth USD 6,521 million by 2030.
Malaysia Blood Plasma Market growth rate is 4.20% during the forecast period.
Increasing Prevalence of Chronic Diseases, Growing Aging Population and Technological Advancements are the growth drivers of the Malaysia Blood Plasma Market.
Type, mode of delivery, therapeutic indication, application, and end-user are the factors on which the Malaysia Blood Plasma Market research is based.
Teva Pharmaceutical Industries Ltd. announced a new strategic framework with four main pillars to position the Company for a new era of growth. This strategy aims to bolster the Company’s strong commercial portfolio with AUSTEDO®, AJOVY®,UZEDYTM and biosimilars, amplify its innovative pipeline, sustain its generics powerhouse and focus the business and wholly-owned subsidiary of Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) and Sun Pharma Advanced Research Company Ltd are the latest developments in the Malaysia Blood Plasma Market.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials